2008 Financial Outlook
The Company is reiterating its adjusted earnings per fully diluted share guidance for 2008 to be in the range of approximately $2.75 - $3.05. The Company expects total revenues for 2008 to be in the range of $2.7 - $2.8 billion, including total product sales in the range of $2.5 - $2.6 billion. On the expense side for 2008, the Company expects investment in R&D to be approximately $285 - $290 million, and SG&A expenses to be approximately $810 - $830 million.
The Company's adjusted earnings guidance for 2008 excludes: the impact of amortization costs associated with acquired products; contributions and/or losses from the DDD&I operations that the Company plans to divest; incremental depreciation related to purchase accounting; the impact of any unscheduled launches resulting from patent challenges; other business development activities; refinancing activities that may be completed after the date hereof and on or before December 31, 2008; and, expenses incurred resulting from the proposed acquisition of Barr by Teva.
The Company will host a Conference Call at 8:30 AM Eastern time on Thursday, August 7, 2008 to discuss earnings results for the quarter ended June 30, 2008. The number to call from within the United States is (800) 230- 1059 and (612) 332-0107 Internationally. A replay of the conference call will be available from 10:30 AM Eastern time on August 7, 2008 through 11:59 PM Eastern time August 21, 2008 and can be accessed by dialing (800) 475-6701 in the United States or (320) 365-3844 Internationally and using the access code 930193.
The Conference Call will also be Webcast live on the Internet.
Investors and other interested parties may access the live webcast through
|SOURCE Barr Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved